Cambridge Healthtech Institute’s Second Annual
Biologics for Autoimmune Diseases
Emerging Targets, Therapeutic Strategies and Product Formats for a Growing Market
Part of the 11th Annual PEGS: the essential protein engineering summit
May 4-5, 2015 | World Trade Center | Boston, Massachusetts


The specificity, efficacy and safety profiles of biologics make them good candidates for the treatment of the complex array of autoimmune diseases, but challenges remain related to clinical endpoints, isolation of responder populations and how to best develop and apply treatment combinations. Emerging genetic understandings of the mechanisms of these complex disorders are now being combined with exciting new therapeutic formats and strategies in a renewed wave of attention for the use of biotherapeutics in this therapeutic area. Biologics for Autoimmune Diseases presents a focused meeting that will offer an exciting exploration of ways in which the industry is applying new science and technology in the development of a next generation of effective and safe therapeutics.

Topics will include, but are not limited to: 

  • Emerging biologic targets and mechanisms of action
    • co-inhibitors and co-stimulators
    • CSF-1
    • dendritic cells
    • gamma-interferon
    • GM-CSF
    • inflammatory cytokines
    • regulatory B-cells
    • T-cells
    • targeting the microbiome
    • toll-like receptors
    • Th17 axis
  • Applying a network biology approach to target and pathway discovery
  • Biologics for inflammatory disorders
  • Biomarkers and companion diagnostics
  • Current status and evolution of TNF-blocking biologics
  • Emerging autoimmune indications for biotherapeutics
  • Endpoints and clinical trial design
  • New biologic product formats for autoimmune diseases
  • Rational design of treatment combinations for autoimmune diseases
  • Second-generation biotherapeutics for RA, IBD, T1D


Scientists who wish to present their knowledge and expertise to their colleagues are asked to click here to submit an abstract. Remember to specify the conference that you are interested in and please provide your full contact information.

Deadline for submission is October 3, 2014. 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For more details on the conference, please contact:
Kent Simmons
Program Director
Cambridge Healthtech Institute
Phone: 207-869-9199
E-mail: ksimmons@healthtech.com 

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452
E: jgerardi@healthtech.com 

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471
E: dinerstein@healthtech.com